Antibodies against cancer antigen TMEFF2 and uses thereof
View Patent ↗Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.
1. A hybridoma cell line deposited as ATCC Accession No. PTA-4127.
2. An isolated monoclonal antibody produced by the hybridoma cell line of claim 1 or an antigen binding fragment thereof.
3. An isolated antibody comprising the heavy chain variable region of SEQ ID NO: 2 and the light chain variable region of SEQ ID NO: 4.
4. The isolated antibody of claim 3 , wherein the heavy chain variable region is encoded by the nucleic acid sequence of SEQ ID NO: 1 and the light chain variable region is encoded by the nucleic acid sequence of SEQ ID NO: 3.
5. The antibody of claim 3 , wherein the antibody is conjugated to an effector moiety.
6. The antibody of claim 5 , wherein the effector moiety is a detectable label.
7. The antibody of claim 5 , wherein the effector moiety is a cytotoxic agent.
8. The antibody of claim 7 , wherein the cytotoxic agent is selected from the group consisting of diphtheria A, exotoxin A, ricin A, abrin A, curcin, crotin, phenomycin, neomycin, and auristatin.
9. The antibody of claim 8 , wherein the cytotoxic agent is auristatin.
10. The antibody of claim 7 , wherein the cytotoxic agent is a radioisotope.
11. A pharmaceutical composition comprising the monoclonal antibody of claim 2 .
12. A pharmaceutical composition comprising the antibody of claim 3 .
13. An isolated humanized antibody comprising the complementary determining regions (CDRs) of SEQ ID NOs: 2 and 4.
14. A pharmaceutical composition comprising the humanized antibody of claim 13 .